RRC ID |
1590
|
Author |
Ogawa F, Iinuma H, Okinaga K.
|
Title |
Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells.
|
Journal |
Scand J Immunol
|
Abstract |
We examined the preventive and therapeutic effects of fusion cells prepared from spleen-derived dendritic cells (DCs) transduced with the interleukin-2 (IL-2) gene and QRsP fibrosarcoma cells in a mouse lung metastasis model. The IL-2 or LacZ gene was introduced into spleen-derived DCs using an adenoviral vector. Irradiated QRsP tumour cells were fused with IL-2 gene-transduced DCs (fusion/IL-2) or LacZ gene-transduced DCs (fusion/LacZ) by polyethylene glycol. These fusion cells expressed major histocompatibility complexes (MHC) class I and II, CD86, CD11c and CD8alpha. Splenocytes from mice vaccinated with fusion cells showed increased production of interferon-gamma (IFN-gamma) and cytotoxic T-lymphocyte (CTL) activity as compared with those vaccinated with DCs or tumour cells alone, and CTL levels were higher in fusion/IL-2-vaccinated mice than in fusion/LacZ-vaccinated mice. In our experiments on the protective and therapeutic effects on lung metastasis, mice vaccinated with fusion/IL-2 fusion/LacZ or fusion showed a significant reduction in pulmonary metastasis compared with those given DCs, tumour or phosphate-buffered saline. The introduction of the IL-2 gene into fusion cells produced more potent preventive and therapeutic effects. These results suggest that immunization with fusion cells prepared from spleen-derived DCs and tumour cells is capable of inducing preventive and therapeutic anti-tumour immunity against lung metastasis, and modification by the IL-2 gene may increase anti-tumour efficacy.
|
Volume |
59(5)
|
Pages |
432-9
|
Published |
2004-5-1
|
DOI |
10.1111/j.0300-9475.2004.01411.x
|
PII |
SJI1411
|
PMID |
15140052
|
MeSH |
Animals
Cancer Vaccines / immunology*
Cell Fusion
Cell Line, Tumor
Cytotoxicity Tests, Immunologic
Dendritic Cells / immunology*
Fibrosarcoma / genetics
Fibrosarcoma / immunology
Fibrosarcoma / therapy*
Flow Cytometry
Immunotherapy, Active*
Interferon-gamma / biosynthesis
Interleukin-2 / genetics*
Interleukin-4 / biosynthesis
Lung Neoplasms / prevention & control*
Lung Neoplasms / secondary
Lymphocytes / immunology
Male
Mice
Neoplasm Metastasis / prevention & control
Spleen / cytology
Transduction, Genetic
|
IF |
2.717
|
Times Cited |
19
|
WOS Category
|
IMMUNOLOGY
|
Resource |
DNA material |
AxCAmIL2 (RDB1402) |